Alnylam reports positive topline results from kardia-1 phase 2 dose-ranging study of zilebesiran, an investigational rnai therapeutic in development to treat hypertension in patients at high cardiovascular risk

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. nasdaq: alny), the leading rnai therapeutics company, today announced that the kardia-1 phase 2 study of zilebesiran, an investigational rnai therapeutic targeting liver-expressed angiotensinogen (agt) in development for the treatment of hypertension, met the primary endpoint demonstrating a dose-dependent, clinically significant reduction in 24-hour mean systolic blood pressure (sbp) measured by ambulatory blood pressure monitori.
ALNY Ratings Summary
ALNY Quant Ranking